Skip to main content
The BMJ logoLink to The BMJ
. 2026 May 6;393:e088921. doi: 10.1136/bmj-2025-088921

Aluminium adjuvants in vaccines and potential health effects: systematic review

Pamela Doyon-Plourde 1, Jeffrey Chong 1, Elissa M Abrams 1,2,3, Robert Pless 1, Kelsey Young 1, Matthew Tunis 1, Joseline Zafack 1,✉
PMCID: PMC13147496  PMID: 42091164

Abstract

Objective

To systematically review and critically appraise human evidence on potential health effects of aluminium adjuvanted vaccines.

Design

Systematic review following PRISMA (preferred reporting items for systematic review and meta-analysis) 2020 guidelines.

Data sources

Six databases and trial registries were searched from inception to 3 March 2023 then updated to 27 November 2025. Reference lists of eligible studies were also screened.

Eligibility criteria for selecting studies

Human studies assessing health outcomes after aluminium adjuvanted vaccination, including randomised controlled trials, cohort studies, case series, and ecological studies. Investigational vaccines, case reports, and review articles were excluded.

Data extraction and synthesis

Two reviewers screened studies (with AI assistance for the 2023-25 update), extracted data, and assessed risk of bias (using RoB 2.0, ROBINS-I, or an adapted tool for case series). Certainty of evidence was rated using GRADE (Grading of Recommendations Assessment, Development, and Evaluation).

Results

The review included 59 studies (37 case series, 11 randomised controlled trials, nine cohort studies, two ecological studies). High quality evidence from randomised controlled trials and large cohorts consistently showed no association between aluminium adjuvanted vaccines and serious or long term health outcomes, such as asthma, autism spectrum disorders, or other chronic conditions. Studies on macrophagic myofasciitis were generally small and methodologically limited, and did not provide credible evidence of a causal association (very low certainty). Localised persistent nodules or granulomas were observed infrequently after diphtheria-tetanus-pertussis vaccines, consistent with delayed type hypersensitivity (<1%, self-limited; moderate to low certainty). For common adverse events (eg, headache, myalgia), high certainty randomised controlled trials found no consistent increase in risk with aluminium adjuvanted formulations. When differences were observed, they were small and predominantly mild to moderate in severity. Evidence was dominated by methodologically limited studies, with most case series and ecological studies at serious or critical risk of bias. Conclusions are primarily supported by higher quality randomised controlled trials and cohort evidence.

Conclusions

Current evidence does not support causal associations between aluminium adjuvanted vaccines and serious or long term health outcomes. The most consistently documented reactions were persistent nodules or granulomas that are uncommon, local, and self-limited hypersensitivity reactions. These findings are broadly consistent with post-licensure surveillance findings. The predominance of methodologically limited studies for some outcomes highlights the need for higher quality research.

Systematic review registration

PROSPERO CRD42023462831.

Introduction

Since their introduction by Glenny and colleagues in 1926, aluminium salts have become the most widely used vaccine adjuvants worldwide, incorporated into vaccines against diphtheria, tetanus, and pertussis (including combination vaccines), pneumococcus, meningococcus, human papillomavirus, hepatitis A and B.1 These adjuvants, typically formulated as aluminium hydroxyphosphate sulfate, aluminium phosphate, or aluminium hydroxide, play a critical part in enhancing immune responses and reducing the antigen dose and number of required vaccine administrations needed for protection.2

Despite decades of post-licensure surveillance, questions about potential long term effects of aluminium adjuvanted vaccines continue to arise in scientific and public settings, informed by a body of literature including case reports, narrative reviews, and preclinical research.3 4 5 6 The human evidence addressing these claims has remained fragmented and methodologically variable, and has not recently been comprehensively synthesised.7 8 9 10

Post-licensure surveillance detects safety signals in real time but does not systematically synthesise cumulative human evidence across outcomes and study designs. To address this gap, a rigorous systematic review was conducted to critically appraise human evidence on health effects and aluminium adjuvanted vaccines, with the objective of supporting evidence based decision making and public health communication.

Methods

Protocol registration

This systematic review followed PRISMA (preferred reporting items for systematic review and meta-analysis) 2020 guidelines and Cochrane guidance.11 The protocol was registered in PROSPERO (CRD42023462831).12

Search strategy

A comprehensive search strategy was developed in Medline (Ovid) by a research librarian and reviewed using the Peer Review of Electronic Search Strategies (PRESS) checklist (supplementary table 1).13 English and French studies were eligible based on reviewers’ language proficiency. Animal only studies and editorials were excluded at the search stage to restrict the review to primary human evidence.

The Medline (Ovid) strategy was adapted for Embase (Ovid), Global Health (Ovid), Cochrane Central Register of Controlled Trials (Ovid), ProQuest Public Health, and Scopus (supplementary tables 2-6). We also searched ClinicalTrials.gov, the EU Clinical Trials Register, and the World Health Organization (WHO) International Clinical Trials Registry Platform (supplementary tables 7-9). Searches were first conducted on 3 March 2023 and updated on 27 November 2025. Records were deduplicated using RefWorks (ProQuest LLC, Ann Arbor, MI, USA) and uploaded to DistillerSR (Evidence Partners Inc, Ottawa, Canada) for screening.

Study selection

Screening forms were piloted before use. Two reviewers (PD-P and JC) independently screened titles and abstracts and full text for the 2023 search. Disagreements were resolved by consensus (PD-P and JC) or third reviewer (JZ) adjudication. We used an AI assisted tool, otto-SR, to support screening of records identified in the 2025 updated search (appendix 1).14 For the 2025 search, all records were flagged as potentially eligible, uncertain, or excluded by otto-SR and then manually reviewed by one reviewer (PD-P), confirmed through independent verification (JZ). We screened reference lists of included studies for additional eligible publications.

Eligibility criteria

Studies were eligible if they reported on health outcomes after exposure to aluminium adjuvants included in vaccines. Comparative studies were included if aluminium adjuvanted vaccines were assessed against a comparator not including aluminium adjuvants (eg, placebo, no intervention, unadjuvanted vaccine, or with a different adjuvant), or with a vaccine containing another aluminium formulation or concentration because they could inform aluminium formulation or dose-response associations. Studies comparing vaccines with similar aluminium formulations were excluded because they cannot appropriately assess the potential effects of aluminium adjuvant. We also excluded investigational vaccines because findings from products not authorised for use cannot be directly applied to existing immunisation programmes, and individual case reports as they cannot distinguish a vaccine related event from a coincidental occurrence. Case series of two or more people were eligible because they allow preliminary assessment of whether a pattern of association exists. We also excluded narrative or systematic reviews, editorials, and opinion pieces. No restrictions were placed on timing, population, or settings.

We identified potential eligible outcomes through an informal preliminary literature search before protocol registration. Eligible studies were not restricted to these outcomes, and any study reporting on health effects of aluminium adjuvanted vaccines and meeting all other inclusion criteria was included. Potential eligible outcomes included but were not limited to persistent nodules or granulomas, headache, myalgia, hypersensitivity reactions, asthma, autoimmune or autoinflammatory syndrome induced by adjuvants, macrophagic myofasciitis (MMF), antiphospholipid syndrome, chronic conditions, autism spectrum disorders (ASD), primary ovarian insufficiency or failure, complex regional pain syndrome, and postural orthostatic tachycardia syndrome.

Data extraction

A standardised extraction form was developed and piloted. One reviewer (JC or PD-P) extracted all data and a second (PD-P or JC) independently verified entries against source studies. Discrepancies were resolved by discussion, and if unresolved, by adjudication with a third reviewer (JZ). Extracted information included study design, population, exposures and comparators, outcome definitions, analytical approaches, effect measures, and limitations. We contacted authors (three attempts) for missing information.

Quality assessment and results synthesis

Two reviewers (PD-P or JC) independently assessed risk of bias using RoB 2.0 for randomised controlled trials,15 ROBINS-I for non-randomised studies,16 and a modified ROBINS-I for case series.17 Certainty of evidence was assessed with GRADE (Grading of Recommendations Assessment, Development, and Evaluation), considering risk of bias, inconsistency, indirectness, and publication bias.18 19 Owing to substantial heterogeneity in study designs, outcome definitions, comparator types, and target populations across included studies, meta-analysis was not feasible and results are presented as a narrative synthesis structured by outcome.

Patient and public involvement

Patients or members of the public were not involved in the design, conduct, reporting, or dissemination plans of this systematic review. All health outcomes with eligible studies were included; potential outcomes identified in a preliminary review were used to inform the search strategy, not studies’ inclusion or exclusion.

Results

Study selection

Initially, 45 articles met the inclusion criteria,20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 11 more were identified from reference lists,41 65 66 67 68 69 70 71 72 73 74 and three additional studies were identified from the 2025 updated literature search (supplementary figure 1),75 76 77 yielding a total of 59 included studies (fig 1).

Fig 1.

Fig 1

PRISMA (preferred reporting items for systematic review and meta-analysis) flowchart for new systematic reviews that included searches of databases and registers

Study characteristics

Included studies (1971-2025) comprised 37 case series, 11 randomised controlled trials, nine cohort studies (including one single arm cohort), and two ecological studies (table 1, table 2, table 3). Most studies (n=33) enrolled children or adolescents.

Table 1.

Characteristics of studies performed from 1971 to 2003

Author, year Country Study design Study period Population Intervention Control Outcome Risk of bias
Erdohazi, 197120 England Case series 1969-70 Children with lump or nodule (n=2) Aluminium hydroxide vaccine (DTP and TT) NA Granulomas Critical*
Pembroke, 197921 UK Case series NR Children with itching nodules at site of previous injections (n=3) Aluminium hydroxide adsorbed vaccines (DT and DTP) NA Persistent nodules, contact allergy Critical*
Slater, 198222 NR Case series NR Children with subcutaneous nodules (n=3) Aluminium hydroxide adsorbed vaccine (DTP) NA Granulomas Critical*
Fawcett, 198469 UK Case series NR Patients with single or multiple nodules at the site of previous injections (n=3; 2 children and 1 adult) Aluminium adsorbed vaccines (DTP, DT, and TT) NA Granulomas Critical*
Veien, 198666 Denmark Case series 1 January 1982 to 30 June 1986 Patients with itchy lesions at sites of childhood immunisation (n=4; children) Aluminium hydroxide vaccine (Di-Te-Pol vaccine) NA Persistent nodules, contact allergy Serious*
Cox, 198865 NR Case series NR Children with persistent symptoms at vaccination sites (n=3) Aluminium adsorbed DTP vaccine NA Persistent nodules, contact allergy Serious*
Cosnes, 199068 NR Case series NR Women with itchy nodules at previous injection sites (n=2) HBV (Hevac B, Pasteur) NA Persistent nodules, contact allergy Critical*
Kaaber, 199223 NR Case series NR Children who had had granulomas for more than 1 year (n=23) Aluminium hydroxide vaccine (Di-Te-Pol vaccine) NA Granulomas
Contact allergy
Serious*
Cominos, 199367 Australia Case series NR Woman with itchy lump (n=2; 1 adolescent and 1 adult) Aluminium phosphate adjuvant adsorbed tetanus toxoid vaccination NA Granulomas Critical*
Miliauskas, 199372 NR Case series NR Patients with single subcutaneous nodule at site of previous injection (n=4; 3 children and 1 adolescent) Aluminium adsorbed vaccines (DTP and TT) NA Granulomas Serious*
Blennow, 199424 Sweden Cohort study January to June 1990 10 year old children (n=517) Booster dose of DT vaccine adsorbed to aluminium phosphate NA Headache Critical†
Skowron, 199825 NR Case series NR Adults with persistent nodule at injection site (n=4) HBV (Genhevac B Pasteur, n=3 and Engerix B, n=1) NA Persistent nodules, contact allergy Critical*
Authier, 200126 France Case series NR Seven patients with MMF with symptomatic demyelinating central nervous system disorder (all adults) Aluminium containing vaccines (HBV, and tetanus) NA MMF Serious*
Bordet, 200127 NR Case series NR Children with subcutaneous nodules at previous injection site (n=3) Aluminium adsorbed DTwP-IPV (Tetracoq vaccine) NA Granulomas Serious*
Chérin, 200171 France Case series 1978-99 Three patients with inclusion body myositis and associated MMF (all adults) Aluminium containing vaccines (HBV, HAV, and tetanus) NA MMF Serious*
Gherardi, 200128 France Case series 1993 to 31 August 1999 All patients with MMF detected during study period (2 children and 48 adults) Aluminium hydroxide containing vaccines (HBV, HAV, and tetanus) NA MMF Moderate*
Guis, 200229 France Case series 1993-97 Two 64 year old identical twins with MMF HBV (Engerix B containing aluminic hydroxide) NA MMF Serious*
Lacson, 200230 North America Case series NR Two children with MMF Age appropriate immunisation NA MMF Critical*
Authier, 200331 France Case series NR Consecutive patients with MMF (n=30, adolescents and adults) Aluminium containing vaccine before onset of symptoms NA MMF Critical*
Bergfors, 200378 Sweden Case series (based on participants from multiple studies or trials) 1991-2002 Infants and children with itching nodules who participated in vaccine studies (n=645) Aluminium hydroxide adsorbed DT, DTaP, and aP vaccines NA Persistent nodules, contact allergy Moderate*

aP=acellular pertussis; DT=diphtheria-tetanus; DTaP=diphtheria-tetanus-acellular pertussis; DTwP-IPV=diphtheria-tetanus-whole cell pertussis inactivated poliovirus vaccine; DTP=diphtheria-tetanus-pertussis; HAV=hepatitis A vaccine; HBV=hepatitis B vaccine; HPV=human papillomavirus; MMF=macrophagic myofasciitis; NA=not applicable; NR=not reported; TT=tetanus toxoid.

*

Risk of bias assessed using modified Cochrane Risk of Bias in Non-randomised Studies in Interventions (ROBINS-I) tool.

†

Risk of bias assessed using Cochrane Risk of Bias in Non-randomised Studies of Interventions (ROBINS-I) tool.16

‡

Risk of bias assessed using the Revised Cochrane risk-of-bias tool for randomised trials (RoB 2).15

Table 2.

Characteristics of studies performed from 2005 to 2015

Author, year Country Study design Study period Population Intervention Control Outcome Risk of bias
Bergfors, 200532 Norway, Sweden Case series May 1999 to April 2005 Children with pruritic nodules (n=19) DTaP-IPV-Hib (Infanrix, Pentavac) NA Persistent nodules, contact allergy Moderate*
Bovier, 200570 Switzerland RCT, crossover trial NR Healthy adults (n=118) Aluminium adsorbed HAV (Havrix 1440) Virosomal HAV (Epaxal) Headache Low‡
Maubec, 200533 NR Case series 1993-2003 Patients with persistent cutaneous lesions at site of previous injection (n=9; adolescent and adults) Aluminium hydroxide adsorbed HBV and HAV vaccines (Havrix, Engerix B and GenHevac B) NA Persistent lumps or nodules, contact allergy Serious*
Rivas, 200534 Spain Case series January 1998 to December 2003 Seven children with MMF HBV at 0, 2, and 6 months and TT vaccine at 2, 4, 6, and 18 months NA MMF Moderate*
Chong, 200635 NR Case series NR Patients with persistent deep dermal and subcutaneous swellings (n=14; children, adolescents, and adults) Aluminium hydroxide vaccines (HBV, TT, DT) NA Granulomas Critical*
Clarke, 200636 UK RCT phase 4 19 August 2003 to 31 August 2004 Healthy people aged 2 years and older (n=540; children, adolescents, and adults) Aluminium adsorbed HAV (Havrix Monodose for adults and Havrix Junior in children <16 years) Aluminium free virosomal HAV (Epaxal) Headache High‡
Kalil, 200737 Brazil Case series NR Three children with MMF Age appropriate immunisation (including HBV) NA MMF Critical*
Lach, 200838 NR Case series NR Eight children with MMF DTP, MMR, hepatitis B, Haemophilus influenzae vaccination NA MMF Serious*
Surquin, 201039 Belgium, Hungary, Czech Republic RCT phase 3 23 February 2006 to 14 July 2006 Patients ≥15 years with renal insufficiency (n=300; adolescents and adults, likely mostly adults) Aluminium adjuvanted HBV (FENDrix, HB-AS04) Non-aluminium adjuvanted HBV (HB-AS02) Headache Low‡
Tomljenovic, 201140 United States, UK, Australia, Canada, Sweden, Finland, Iceland Ecological study 1991-2008 Children and adolescents aged 6-21 years Aluminium exposure (μg) from paediatric vaccines (given <6 years old) and number of aluminium adjuvanted vaccines in yearly vaccination schedule NA ASD Critical†
Bergfors, 201341 Sweden Case series 1999-2011 Patients with persistent itching nodules after DTP vaccination (Infanrix and Pentavac) between 1999 and 2011 (n=64; children) Aluminium hydroxide vaccines (DTaP-IPV and DTaP/IPV-Hib vaccines) NA Persistent nodules, contact allergy Moderate*
Lidholm, 201342 Sweden Case series October 2007 to May 2008 Children with itching nodules after vaccination and showing aluminium allergy 5-9 years before (n=241) Aluminium hydroxide adsorbed DT, DTaP, and aP vaccines NA Persistent nodules, contact allergy Serious*
Ragunathan-Thangarajah, 201343 France Retrospective single arm cohort study NR Consecutive patients with arthro-myalgia previously immunised with aluminium containing vaccines (n=130; adolescents and adults) Aluminium containing vaccine (ie, HBV, HAV, TT, Revaxis, Infanrix vaccines) NA MMF Critical†
Basavaraj, 201444 India RCTs phase 1 Phase 1: January-February 2010 Healthy adults aged 18-65 years (n=160) Aluminium adjuvanted monovalent MDCK based H1N1 pandemic influenza vaccine Unadjuvanted monovalent MDCK based H1N1 pandemic influenza vaccine; adjuvanted placebo; unadjuvanted placebo Headache Low‡
Bergfors, 201473 Sweden Cohort 2009 to January 2014 Children in Östergötland County, Sweden born in 2008 (n=4758) DTP-polio-Hib (Infanrix, Pentavac, Prevenar) NA Granulomas, contact allergy Critical†
Konno, 201445 Japan RCT phase 3 June 2009 to February 2011 Women aged 20-25 years HPV-16/18 AS04-adjuvanted vaccine (Cervarix, GSK vaccines) Aluminium free hepatitis A vaccine (Aimmungen, Kaketsuken) Chronic conditions Some concerns‡
Nevison, 201446 United States Ecological study 1991-2010 Children aged 6-17 years Cumulative amount of aluminium adjuvants administered postnatally by 18 months NA ASD Critical†
Meulen, 201547 Finland, United States RCT phase 1 September 2009 to March 2010 Healthy, afebrile children aged 12-15 months who previously completed a 3 dose series of PCV7 (n=90) Aluminium adjuvanted PCV15, aluminium adjuvanted PCV7 Unadjuvanted PCV15 Myalgia Low‡
Santiago, 201548 Portugal Case series January 2003 to July 2013 Patients with MMF (n=16; adults) Aluminium containing vaccines NA MMF Serious*
Van Der Gucht, 201549 France Case series NR Patients with MMF and cognitive symptoms (n=76; adults) Aluminium containing vaccines NA MMF Serious*

aP=acellular pertussis; ASD=autism spectrum disorders; DT=diphtheria-tetanus; DTaP=diphtheria-tetanus-acellular pertussis; DTaP-IPV-Hib=diphtheria-tetanus-acellular pertussis inactivated poliovirus-Haemophilus influenzae type b; DTP=diphtheria-tetanus-pertussis; HAV=hepatitis A vaccine; HBV=hepatitis B vaccine; HPV=human papillomavirus; MDCK=Madin-Darby canine kidney; MMF=macrophagic myofasciitis; MMR=measle mumps rubella; NA=not applicable; NR=not reported; PCV=pneumococcal conjugate vaccine (general); PCV7=7-valent pneumococcal conjugate vaccine; PCV15=15-valent pneumococcal conjugate vaccine; RCT=randomised controlled trial; TT=tetanus toxoid.

*

Risk of bias assessed using modified Cochrane Risk of Bias in Non-randomised Studies in Interventions (ROBINS-I) tool.

†

Risk of bias assessed using Cochrane Risk of Bias in Non-randomised Studies of Interventions (ROBINS-I) tool.16

‡

Risk of bias assessed using the Revised Cochrane risk-of-bias tool for randomised trials (RoB 2).15

Table 3.

Characteristics of studies performed from 2016 to 2025

Author, year Country Study design Study period Population Intervention Control Outcome Risk of bias
Leroux-Roels, 201650 Belgium, Germany RCT phase 2 December 2008 to July 2011 Healthy adults 18-45 years (n=710) HBsAg-Aluminium (2 doses: day 0 and 30) HBsAg-AS01B, HBsAg-AS01E, HBsAg-AS03A, or HBsAg-AS04 (2 doses: day 0 and 30) Headache, myalgia Some concerns‡
Salik, 201674 Denmark Case series January 2003 to October 2013 Children aged ≤10 years with persistent skin reactions after vaccination (n=47) DTaP-IPV/Hib, PCV, MMR, and BCG vaccination NA Persistent nodules, contact allergy Serious*
Poddighe, 201751 Italy Case series 2015 Young girls 12-24 years with somatoform, neurological, and vasomotor symptoms (n=18; adolescents and adults) 4vHPV (Gardasil), 2vHPV (Cervarix) NA Headache, myalgia, somatoform and neurocognitive symptoms Serious*
Burny, 201952 Belgium RCT phase 2 January 2013 to September 2016 Healthy adults 18-45 years (n=149) HBsAg-Aluminium (Engerix B, 3 doses: day 0, 30 and 180) HBsAg-AS01B (2 doses: day 0 and 30) Headache, myalgia Low‡
Sechi, 201953 Italy Case series NR Children with vaccination granuloma (n=3) Second booster dose of aluminium hydroxide DTaP-HB-IPV-Hib (Infanrix-Hexa) or aluminium phosphate PCV13 (Prevenar 13) NA Granulomas, contact allergy Critical*
Fournier, 202054 NR Case series NR Children presenting with pruriginous annular plaques (n=2) Aluminium hydroxide vaccines: HBV (Recombivax HB) and HPV (Cervarix and Gardasil 9) NA Hypersensitivity Critical*
Hoffmann, 202055 Denmark Cohort study 1 January 2010 to 1 September 2018 Children aged ≤15 years with suspected contact allergy (n=238) Aluminium adjuvanted vaccine (DiTeKiPol/Hib) Vaccine not containing aluminium (MMR vaccine) Granulomas, contact allergy Critical†
Kelly, 202056 Ireland Case series 2010-18 Children with suspected vaccination granulomas (n=13) Aluminium salts adjuvanted vaccine (DTaP-IPV/HiB) NA Granulomas contact allergy Serious*
Kim, 202057 Korea Case series 2015-19 Seven children with MMF HBV, HAV, and TT vaccines NA MMF Moderate*
Zanoni, 202058 Italy Case series 2016-19 Children with localised reactions owing to suspected allergy to vaccine components (n=8) Children 5-8: aluminium adjuvanted MenB and hexavalent vaccine NA Persistent nodules, contact allergy Serious*
Glanz, 202159 United States Retrospective cohort study 1 January 2004 to 31 December 2019 Children born from 1 January 2004 to 31 December 2014 identified from VSD databases Cumulative aluminium exposure (mg) from vaccines up to 23 months of age NA Type 1 diabetes mellitus Moderate†
Hoffmann, 202260 Denmark Cohort study 1 January 2009 to 31 December 2020 Children born in Denmark between 1 January 2009 and 31 December 2018 (n=553 932) DTaP-IPV-HiB and PCV NA Granulomas Moderate†
Lidholm, 202261 Sweden Case series 1997-19 People who participated in Gothenburg trial with itching nodules at aP vaccination site (n=745; children) Aluminium hydroxide vaccines (aP or DTaP and DT booster) NA Persistent nodules, contact allergy Serious*
Walsh, 202262 United States RCT phase 1/2 April 2018 to November 2019 Healthy adults 18-49 years (n=618) Aluminium hydroxide RSVpreF vaccine (120 µg) Non-adjuvanted RSVpreF vaccine (120 µg) Headache, myalgia Low‡
NCT04032093, 202263 United States, Argentina, Chile, New Zealand, South Africa RCT phase 2b 7 August 2019 to 30 September 2021 Pregnant women at 24-36 weeks’ gestation (n=587; adults) Aluminium hydroxide RSVpreF vaccine (120 µg) Non-adjuvanted RSVpreF vaccine (120 µg) Headache Low‡
Daley, 202364 United States Retrospective cohort study 1 January 2008 to 31 December 2017 Children born from 1 January 2008 to 31 December 2014 receiving care at a VSD site (n=326 991) Cumulative aluminium exposure (mg) from vaccines before 24 months of age NA Persistent asthma at 24-59 months of age Moderate†
Ackerson, 202376 United States Prospective cohort study 7 August 2017 to 30 November 2020 KPSC members ≥18 years vaccinated with HBV between 7 August 2017 and 31 October 2019 (n=69 625) Aluminium hydroxide HBV (Engerix-B) Non-aluminium adjuvanted HBV (Heplisav-B) New onset immune mediated conditions Moderate†
Marks, 202577 United States, South Africa, Botswana, Kenya, Malawi, Uganda, Thailand, Vietnam, Philippines, Brazil RCT phase 3 1 December 2020 to 4 September 2023 Adults ≥18 years with HIV and previous vaccine non-response (n=561) Aluminium hydroxide HBV (Engerix-B) Non-aluminium adjuvanted HBV (Heplisav-B) Headache, myalgia Low‡
Andersson, 202575 Denmark Retrospective cohort study 1 January 1997 to 31 December 2020 Children born from 1 January 1997 to 31 December 2018 who were alive and residing in the country at 2 years of age (n=1 224 176) Cumulative aluminium exposure (mg) from childhood vaccines received by 2 years of age NA Autoimmune disorders, atopic or allergic outcomes (including asthma and allergy), neuro-developmental disorders (including ASD) Moderate†

2vHPV=bivalent human papillomavirus vaccine; 4vHPV=quadrivalent human papillomavirus vaccine; aP=acellular pertussis; ASD=autism spectrum disorders; BCG=Baccile Calmette-Guérin vaccine; DT=diphtheria-tetanus; DTaP=diphtheria-tetanus-acellular pertussis; DTaP-HB-IPV-Hib=diphtheria-tetanus-acellular pertussis-hepatitis b inactivated poliovirus-Haemophilus influenzae type b; DTaP-IPV-Hib=diphtheria-tetanus-acellular pertussis inactivated poliovirus-Haemophilus influenzae type b; HAV=hepatitis A vaccine; HBV=hepatitis B vaccine; HBsAg=hepatitis B surface antigen (antigen only, no adjuvant); HBsAg-AS01B=hepatitis B surface antigen adjuvanted with AS01B; HBsAg-AS01E=hepatitis B surface antigen adjuvanted with AS01E; HBsAg-AS03A=hepatitis B surface antigen adjuvanted with AS03A; HBsAg-AS04=hepatitis B surface antigen adjuvanted with AS04; HPV=human papillomavirus; KPSC=Kaiser Permanente Southern California; MenB=serogroup B meningococcal vaccine; MMF=macrophagic myofasciitis; MMR=measle mumps rubella; NA=not applicable; NR=not reported; PCV=pneumococcal conjugate vaccine (general); PCV13=13-valent pneumococcal conjugate vaccine; RCT=randomised controlled trial; RSVpreF=respiratory syncytial virus prefusion F protein vaccine; TT=tetanus toxoid; VSD=Vaccine Safety Datalink.

*

Risk of bias assessed using modified Cochrane Risk of Bias in Non-randomised Studies in Interventions (ROBINS-I) tool.

†

Risk of bias assessed using Cochrane Risk of Bias in Non-randomised Studies of Interventions (ROBINS-I) tool.16

‡

Risk of bias assessed using the Revised Cochrane risk-of-bias tool for randomised trials (RoB 2).15

Investigated outcomes included ASD,40 46 75 asthma,64 75 other chronic conditions,45 51 59 75 76 MMF,26 28 29 30 31 34 37 38 43 48 49 57 71 headache,24 36 39 44 50 51 52 62 63 70 77 myalgia,47 50 51 52 62 77 and hypersensitivity reactions (ie, Wells syndrome, persistent nodules, granulomas).21 23 25 32 33 41 42 53 55 56 58 61 65 66 68 73 74 78 No eligible evidence was identified for autoinflammatory syndrome induced by adjuvants, antiphospholipid syndrome, primary ovarian insufficiency or failure, complex regional pain syndrome, or postural orthostatic tachycardia syndrome. Twenty four studies contributed data on more than one outcome.

Risk of bias

Using ROBINS-I, 11 observational studies were assessed: six at critical risk and five at moderate risk mostly owing to confounding (supplementary figure 2). Of the 11 randomised controlled trials assessed with RoB 2.0, eight were at low risk, two had some concerns, and one was at high risk, with issues mostly related to outcome measurement (supplementary figure 3). Most case series were at serious (n=18) or critical (n=13) risk of bias, while six were at moderate risk, with concerns primarily related to participant selection, intervention classification, and selective reporting (supplementary figure 4).

Results of individual studies

Autism spectrum disorders

Three studies reported data on ASD40 46 75 (table 2, table 3). Two ecological studies examined correlations between aluminium in paediatric vaccine schedules at the time (ie, vaccine administered from birth to 18 months or <6 years) and ASD prevalence in the United States (1991-2010), and other high income countries.40 46 Both reported positive correlations40 46; however, neither measured ASD incidence or severity. Aluminium exposure was estimated from vaccine schedule content, representing a feasible proxy available for population level analyses; however, ecological designs cannot adjust for individual level confounders such as diagnostic changes, increased clinical and public awareness of ASD, genetic factors, or environmental exposures, limiting their ability to support causal inference. Both studies were judged at critical risk of bias and the certainty of evidence rated very low (table 4 and supplementary table 10).

Table 4.

Summary of evidence

Outcome Type of evidence Incidence Severity* Methodological limitations Direction of association Certainty of evidence Causal association (conclusion)
Autism spectrum disorder 1 large cohort, 2 ecological studies Rare Serious Confounding, ecological fallacy No association (cohort); positive correlation (ecological studies) Moderate, very low (ecological studies) Not in favour of a causal association
Asthma 2 large cohorts Common Serious Residual confounding No consistent association Moderate Not in favour of a causal association
Chronic conditions† 1 RCT, 3 cohorts, 1 case series Rare Serious Confounding, imprecision No association (RCT, cohorts, case series); inverse association (type 1 diabetes mellitus cohort) Moderate, low (neurofunctional symptoms) Not in favour of a causal association
Macrophagic myofasciitis 12 case series, 1 cohort Not quantifiable (about 210 reports) Serious Selective reporting, selection bias, recall bias Reported association Very low Not in favour of a causal association
Headache 9 RCTs, 1 single arm cohort, 1 case series Common Mostly mild or moderate Confounding and recall bias in non-RCTs No increased risk except for RSVpreF High Not in favour of a causal association for most studies (risk may vary by vaccine)
Myalgia 5 RCTs, 1 case series Common Mostly mild or moderate Selective reporting and recall bias (case series) Slight increased risk with RSVpreF, PCV15; otherwise no difference High Not in favour of a causal association
Wells syndrome 1 case series 2 children Moderate or severe Selection bias Positive association Low Insufficient evidence
Persistent nodules 12 case series, 1 cohort Uncommon (<1%) Mild Selection and misclassification biases, selective reporting Consistent association Low Consistent with a causal association
Granulomas 10 case series, 3 cohorts Uncommon (<1%) Mild or moderate Selection and misclassification biases, selective reporting Consistent association Moderate Consistent with a causal association

PCV15=15 valent pneumococcal conjugate vaccine; RCT=randomised controlled trial; RSVpreF=respiratory syncytial virus prefusion F protein vaccine.

*

Severity rated based on expected impact as mild (minor impact on daily activities), moderate (interfered with but did not prevent daily activities), severe (prevented daily activities), serious (life threatening, results in hospital admission, prolongs existing hospital stay, or causes persistent disability).

†

New onset, type 1 diabetes mellitus, neurofunctional symptoms, autoimmune disorders.

A large nationwide Danish cohort study (1997-2020, n=1 224 176) assessed cumulative aluminium exposure from vaccines received in the first two years of life and found no increased risk of neurodevelopmental disorders overall (adjusted hazard ratio 0.93, 95% confidence interval (CI) 0.90 to 0.97) or ASD specifically (0.93, 0.89 to 0.97; incidence 141 per 100 000 person years), with no dose-response association.75 Risk of bias and certainty were rated moderate (table 4 and supplementary table 10).

Overall, evidence from two methodologically limited ecological studies and one large well controlled cohort does not support a causal association between aluminium adjuvanted vaccines and ASD.

Asthma

Two cohort studies reported data on asthma64 75 (table 3). A large US retrospective cohort study (Vaccine Safety Datalink, 2008-14, n=326 991) evaluated cumulative aluminium exposure before 24 months and persistent asthma incidence between 24 and 59 months.64 Adjusted analyses showed modest associations in children with eczema (adjusted hazard ratio 1.26, 95% CI 1.07 to 1.49) and without eczema (1.19, 1.14 to 1.25).64 However, the statistical significance was not consistently maintained when restricting the analysis to fully vaccinated infants or those who were breastfed. Asthma severity (eg, hospital admission or exacerbation) was not assessed. The study authors attributed the associations in part to unmeasured confounding and exposure misclassifications, and encouraged additional investigations. A recent Danish nationwide cohort study (1997-2020; n=1 224 176) also assessed aluminium exposure from vaccines in the first two years of life and subsequent asthma risk.75 In adjusted models, cumulative aluminium exposure was not associated with increased asthma incidence (adjusted hazard ratio 0.96, 95% CI 0.94 to 0.98; incidence 1395 per 100 000 person years).75 Risk of bias was moderate for the two cohort studies and certainty of evidence was rated moderate (table 4 and supplementary table 10).

Overall, available evidence does not support a causal association between aluminium adjuvanted vaccines and asthma; a modest and inconsistent association observed in one US cohort was not replicated in a larger Danish population based cohort.

Other chronic conditions

One randomised controlled trial,45 three cohort studies,59 75 76 and one case series51 examined potential associations between aluminium adjuvanted vaccines and chronic conditions (table 2, table 3). A Japanese randomised controlled trial (n=1040) followed women for four years after human papillomavirus (HPV)-16/18 AS04 adjuvanted versus aluminium-free hepatitis A (HAV) vaccination finding similar rates of new chronic conditions (1.2%, n=6/519 v 1.5%, n=8/521), indicating no association with aluminium exposure.45 The trial was well conducted, with some concern for bias and moderate certainty (table 4 and supplementary table 10).

A large US cohort study (n=584 171) examined type 1 diabetes mellitus in children aged 2-14 years and found no increased risk with cumulative aluminium exposure (adjusted hazard ratio 0.77, 95% CI 0.60 to 0.99).59 Another large US cohort study (n=69 625) found no increased risk of new onset immune mediated conditions over 13 months of follow-up in adults receiving aluminium adjuvanted compared with non-aluminium adjuvanted hepatitis B (HBV) vaccine.76 More recently, a Danish nationwide cohort study (n=1 224 176) found no increased risk of chronic conditions with cumulative aluminium exposure from vaccines during the first two years of life, including autoimmune conditions (adjusted hazard ratio 0.98, 95% CI 0.94 to 1.02; incidence 0.8-50.5 per 100 000 person years), and atopic or allergic conditions (0.99, 0.98 to 1.01; incidence 1.0-849.9 per 100 000 person years).75 Risk of bias was moderate (n=3) and certainty of evidence was moderate with concerns for confounding bias (table 4 and supplementary table 10).

A small case series of 16 girls who developed somatoform and neurocognitive symptoms after HPV vaccination found no aluminium specific lymphocyte response at testing approximately two years after vaccination; the authors concluded that cell mediated immune activation to aluminium is an unlikely mechanism for the observed neurofunctional symptoms.51 Certainty was low owing to design and sample size limitations, with serious concerns for risk of bias (table 4 and supplementary table 10).

Overall, no evidence supports an association between aluminium containing vaccines and chronic conditions. Evidence is limited by the low incidence in some outcomes, methodological heterogeneity, and low-to-moderate certainty of evidence.

Macrophagic myofasciitis

Thirteen studies (12 case series and one cohort study)26 28 29 30 31 34 37 38 43 48 49 57 71 reported on MMF, with about half conducted in France26 28 29 31 43 49 71 (table 1, table 2, table 3). Across 12 case series,26 28 29 30 31 34 37 38 43 48 49 57 71 210 reports were described, including 28 children, with three large French series accounting for 74% (n=156/210) of reports.28 31 49

All reports of MMF were identified through deltoid muscle biopsy, with 97.6% (n=205/210) investigated for diffuse myalgias, arthralgias, or muscle weakness. Histology consistently showed periodic-acid-Schiff positive macrophage infiltrates, with aluminium inclusions in 39.0% (n=82/210),28 30 34 37 38 48 57 concurrent focal chronic inflammatory reaction in 9.0% (n=19/210),34 48 57 71 and concurrent autoimmune conditions in 23.8% (n=50/210).26 28 29 37 48 57 71 Most people (93.3%, n=196/210) had previous aluminium containing vaccination before biopsy; the interval between vaccination and symptom onset and duration of symptoms varied considerably across studies, with some studies reporting onset and persistence ranging from months to years.31 48

In a French cohort of 130 patients with chronic musculoskeletal pain of at least six months who had received an aluminium adjuvanted vaccine within the preceding 10 years, MMF lesions were detected in 32.3% (n=42/130) at deltoid muscle biopsy. The number of aluminium containing vaccine injections was similar in those with and without lesions (3.2±1.5 v 2.7±1.2), indicating that MMF lesions were absent in most people (67.7%, n=88/130) with similar exposure and comparable symptoms.43

All studies lacked control groups and were limited by selective biopsy referral, incomplete exposure characterisation, and heterogeneous histological reporting. Risk of bias was moderate to critical, and certainty of evidence was very low (table 1, table 2, table 3, table 4, and supplementary table 10). MMF lesions can be detected histologically in some people biopsied in the deltoid of the vaccinated arm; however, current evidence does not support a causal association between MMF lesions and systemic clinical symptoms.

Headache

Eleven studies evaluated headache, typically within one month of aluminium adjuvanted vaccination: nine randomised controlled trials,36 39 44 50 52 62 63 70 77 one single arm cohort,24 and one case series51 (table 1, table 2, table 3). Across four HBV randomised controlled trials, headache frequencies were similar between aluminium adjuvanted and non-aluminium formulations.39 50 52 77 Two HAV randomised controlled trials found no significant differences between aluminium adsorbed and virosomal formulations in headache frequency, though one reported slightly higher frequency with the aluminium formulation (2.7%, n=2/75 v 0.9%, n=3/338; P=0.49).36 70 Two RSVpreF (respiratory syncytial virus prefusion F protein vaccine) randomised controlled trials reported slightly higher headache rates with the adjuvanted formulation (16.5% (n=19/115) to 33.3% (n=4/12) v 8.3% (n=1/12) to 18.4% (n=21/114)), with events predominantly mild or moderate.62 63 A H1N1 influenza randomised controlled trial found no increase in headache with the aluminium formulation.44 Seven randomised controlled trials were at low risk of bias, one had some concerns, and one was at high risk owing to missing data and outcome measurement36 (table 1, table 2, table 3, table 4). Overall, certainty of evidence was high (supplementary table 10).

A single arm cohort found no difference in headache risk between recipients of diphtheria-tetanus vaccine regardless of whether their primary series included aluminium phosphate or non-adjuvanted diphtheria-tetanus-pertussis (DTP).24 A small HPV case series reported headache in only two of 16 people.51 Both were at serious to critical risk of bias, providing moderate certainty of evidence (table 4 and supplementary table 10).

Overall, high certainty randomised controlled trial evidence indicates no consistent increase in headache risk with aluminium adjuvanted vaccines. When differences were observed, they were small, inconsistent across studies, and predominantly mild to moderate in severity.

Myalgia

Six studies (five randomised controlled trials47 50 52 62 77 and one case series51) evaluated myalgia within one month of vaccination (table 2, table 3). Across three randomised controlled trials comparing aluminium adjuvanted with non-aluminium adjuvanted HBV vaccines, two reported fewer myalgia events in aluminium adjuvanted groups and one found similar frequencies.50 52 77 Two randomised controlled trials reported slightly higher myalgia frequencies with aluminium adjuvanted formulations: RSVpreF (50.0%, n=6/12 v 33.3% n=4/12, predominantly mild to moderate) and 15-valent pneumococcal conjugate vaccine (30.3%, n=10/33 v 28.6%, n=8/28, severity not reported).47 62 Four randomised controlled trials had low risk of bias47 52 62 77 and one had some concerns50; certainty was high (table 4 and supplementary table 10). A small HPV case series reported myalgia as a primary symptom in four of 16 people and was rated at serious risk of bias with low certainty of evidence51 (table 4 and supplementary table 10).

Overall, randomised controlled trial evidence does not show a consistent association between aluminium adjuvants and myalgia. When higher frequencies were observed, differences were small and severity was predominantly mild to moderate, while some studies found lower rates with aluminium formulations.

Hypersensitivity reaction: generalised hypersensitivity reactions to aluminium

Wells syndrome—A single case series described two paediatric patients with Wells syndrome occurring 12-14 days after HBV or HPV vaccination, or both54 (table 3). Both patients developed pruritic erythematous or violaceous annular plaques with vesicles; patch testing showed aluminium sensitisation (one patient to aluminium hydroxide and one to aluminium chloride hexahydrate). Symptoms resolved in both patients with a short course of corticosteroids over 2-6 weeks. The study had critical risk of bias owing to selection bias and certainty of evidence was low (table 4 and supplementary table 10). These findings are insufficient to establish causality between aluminium adjuvants and Wells syndrome.

Hypersensitivity reaction: localised delayed-type hypersensitivity to aluminium

Persistent nodules and granulomas are presented separately to reflect the terminology and classification used in the primary studies, noting that granulomas are often considered a possible histopathological subcategory of persistent nodules requiring confirmatory histopathology for diagnosis.

Persistent nodules—Thirteen case series reported 885 non-overlapping events of persistent nodules after aluminium adjuvanted vaccination, several representing longitudinal follow-up of previously described events21 25 32 33 41 42 58 61 65 66 68 74 78 (table 1, table 2, table 3). Most were conducted in Scandinavia (Sweden, n=532 41 42 61 78; Denmark, n=266 74), with others in Italy (n=1)58 and the UK (n=1).21

Among reports with available data (86.6%; n=766/885), nodules developed almost exclusively after DTP or related combination vaccines (98.0%, n=751/766) and after the third dose (75.8%, n=581/766); less often after the second (17.9%, n=137/766) or first (5.0%, n=38/766) dose.25 33 41 58 65 68 74 78 Onset ranged from days to several years after vaccination, with a median of about three months in larger series.33 41 78 Symptoms varied in duration, typically persisting for months to years. Pruritus was common, sometimes severe, and symptoms often (33.0%, n=292/885) worsened during intercurrent infections such as upper respiratory tract infections or gastroenteritis.41 74 78

Across 582 patch tests performed, 80.6% (n=469/582) were positive for aluminium, supporting delayed type hypersensitivity as an underlying mechanism. A large Swedish study (about 76 000 children) found a 0.98% (n=745/76 000) incidence,61 78 with most occurring after the third dose. Symptoms often persisted for years (median four years), with 75.4% (n=473/627) of children still symptomatic at follow-up.78 Exacerbations during intercurrent infections were reported in 38.9%. Aluminium sensitisation occurred in 77.4% (n=352/455) of children with symptoms versus 8.1% (n=17/211) of siblings without symptoms who had received the same vaccines (P<0.0001).78 Long term follow-up showed declining sensitisation: 77.2% (n=186/241) were no longer sensitised after 5-9 years42 and 85.5% (n=637/745) had full symptom resolution after a median of 6.6 years, with low recurrence after boosters.61 Findings were consistent across Scandinavian series, showing similar onset, duration, and hypersensitivity patterns.32 41

Most studies were at serious (n=7) or critical (n=3) risk of bias, and only three at moderate risk (table 1, table 2, table 3). Common issues included selective referral, intervention misclassification, and selective outcome reporting. About one third of the case series (n=5) originated from the same research group; total number of reports was derived accordingly, though residual overlap cannot be excluded. Certainty of evidence was rated low (table 4 and supplementary table 10).

Overall, evidence suggests a reproducible association between aluminium adjuvanted vaccines and persistent nodules, likely mediated by delayed hypersensitivity. Available follow-up data indicate these reactions are local and non-progressive, with declining sensitisation and low recurrence after boosters.

Granulomas—Thirteen studies (10 case series, three cohort studies) reported granulomas, mostly from Europe (n=7) and Australia (n=1), published between 1971 and 202220 22 23 27 35 53 55 56 60 67 69 72 73 (table 1, table 2, table 3).

Among 59 reports of granulomas across 10 case series, most (91.5%, n=54/59) occurred after DTP combination vaccines, with a few after HBV35 or other unspecified aluminium adjuvanted vaccines.35 56 Histology (n=25/59, 42.4% confirmed) showed granulomatous inflammation, often necrotising or fibrotic, with mixed infiltrates of lymphocytes, histiocytes, and eosinophils.20 22 27 35 56 67 69 72 Aluminium was detected in 60.0% (n=15/25) with histological confirmation.20 22 27 67 69 72 Most granulomas appeared after the third dose (88.9% with dose data, n=32/36), consistent with sensitisation; nearly all patch tests were positive (n=32/33). Onset ranged from weeks to years, and lesions typically persisted for two to more than five years.

Cohort incidence estimates ranged from 0.34% (n=1901/553 932)60 to 0.83% (n=38/4558).73 Granulomas were often pruritic, with symptoms exacerbated by intercurrent infections or aluminium exposures (eg, sunscreen, canned food).55 73 Reported risk factors included higher aluminium dose (>1.0 mg), aluminium hydroxide adjuvant, revaccination, and female sex.60 Having an affected sibling was the strongest predictor (rate ratio 46.15, 95% CI 33.67 to 63.26). Combination adjuvants (hydroxide plus phosphate), prematurity, and younger maternal age (<20 years) were associated with lower risk. Most granulomas occurred before age 2, peaking after the third dose.60

Risk of bias was high across case series (serious, n=4; critical, n=6) and mixed in cohorts (one moderate, two critical; table 1, table 2, table 3). Limitations included confounding, selection and misclassification biases, and selective reporting, as well as lack of standardised histopathology and incomplete follow-up (table 4). Certainty of evidence was judged moderate (supplementary table 10).

Granulomas are uncommon but consistently reported after aluminium adjuvanted DTP vaccination, typically after the third dose and associated with aluminium hypersensitivity. Cohort data provide incidence estimates and identify potential risk factors including a possible dose-response association, though methodological limitations preclude definitive causal inference.

Discussion

Principal findings

This systematic review finds that human evidence does not support causal associations between aluminium adjuvanted vaccines and serious or long term health outcomes. High quality evidence from randomised controlled trials and large cohort studies consistently showed no association between aluminium adjuvants in vaccines and systemic conditions, including ASD, type 1 diabetes mellitus, asthma, headache, myalgia, and other chronic conditions. Although histological MMF deposits were identified in a subset of people who had biopsies for musculoskeletal symptoms after vaccination, available evidence does not establish how, if at all, these local aluminium inclusions relate to systemic symptoms. For Wells syndrome, a single small case series raised only the possibility of a rare hypersensitivity response without sufficient evidence for causal inference. The only consistently observed events were uncommon, local hypersensitivity reactions (ie, persistent nodules and granulomas) supported by convergent clinical, histological, and patch test evidence suggesting a delayed type hypersensitivity mechanism, which though self-limited may cause prolonged discomfort.

The strength of conclusions varies across outcomes and reflects a clear gradient in study quality. Randomised controlled trials at low risk of bias provide the most reliable evidence, with null findings for chronic conditions and increase in risk of headache and myalgia observed in some studies. Large cohort studies at moderate risk of bias similarly found no association with serious systemic outcomes such as asthma, type 1 diabetes mellitus, and ASD. By contrast, most case series and both ecological studies are structurally limited in their ability to support causal inference, therefore findings pertaining to MMF and ASD derived from these studies should be considered hypothesis generating. The evidence base was dominated by methodologically limited studies and conclusions should be interpreted accordingly. Taken together, the convergent findings of higher quality studies provide a meaningful evidence base to inform public health decision making on aluminium adjuvanted vaccines.

Comparisons with other studies

These findings align with previous systematic reviews and post-licensure surveillance evaluations finding no increased risks of chronic diseases attributable to aluminium adjuvanted vaccines, and align with conclusions reached by the WHO Global Advisory Committee on Vaccine Safety for ASD, MMF, and other serious outcomes.5 6 7 8 9 10 79 The positive correlations reported in the two ecological studies are limited by their inability to control for confounding and absence of individual level exposure data, contrasting with the large Danish cohort included in this review and several large epidemiological studies finding no association between vaccination and ASD.75 80 81 82 For MMF, a French cohort study found a similar number of previous aluminium containing vaccine injections in those with and without MMF lesions, providing no evidence of dose-response association.43 Further contextual support comes from patients receiving allergen immunotherapy, who accumulate substantially higher cumulative aluminium doses without increased risk of autoimmune disease, and from pharmacokinetic modelling, suggesting the total aluminium contained within recommended childhood vaccine schedules falls well below established reference values.83 84 The geographical concentration of nodule and granuloma evidence in Scandinavia and MMF evidence in France raises questions about whether these patterns reflect local scientific interest and reporting practices, population level phenomena, regional formulation differences, or local referral practices, a consideration not addressed in previous reviews.

Interpretation of these findings should consider differences in scope and eligibility criteria between this review and previous systematic reviews on aluminium adjuvants.10 85 This review excluded investigational or candidate vaccines and was restricted to studies including a vaccine authorised for use. Studies with similar aluminium formulations and dosage between the intervention and comparator were also excluded because they do not allow isolation of the potential effects of aluminium adjuvants. While these eligibility criteria resulted in fewer included studies, they ensure that findings specifically reflect the evidence on vaccines used in immunisation programmes, which is most directly relevant to clinical and public health decision making.

Strengths and limitations of this study

Strengths of this review include its comprehensive search strategy, application of validated risk-of-bias tools, GRADE certainty assessment, and incorporation of evidence to November 2025. Important limitations remain. Evidence on specific vaccine components is sparse compared with whole vaccine research, with a high proportion of methodologically weak studies, predominantly from high income countries. Randomised controlled trials comparing identical formulations with and without aluminium adjuvants remain logistically and ethically challenging for rare or delayed outcomes requiring large sample sizes and extended follow-up. Most studies were uncontrolled case series from a small number of investigators. Despite efforts to exclude overlapping populations, residual overlap cannot be excluded, and true incidence estimates may be conservative or inflated. Very rare reactions may be underrepresented given the exclusion of individual case reports. The search strategy could not be fully updated in ProQuest owing to platform limitations. The absence of patient and public involvement is acknowledged as a limitation, particularly for outcomes such as ASD and MMF when community perspectives are relevant.

Further research should examine individual susceptibility factors including sex, ethnicity, family history, adjuvant type, and aluminium dose, while accounting for total exposure from non-vaccine sources such as diet, antacids, breast milk and formula.86 Sex and gender disaggregated data were rarely reported in primary studies, limiting the evaluation of potential differences in health risks. Although granulomas are considered a histopathological subcategory of persistent nodules, the clinical and biological boundary between the two reactions in the absence of confirmatory histology remains unclear, and whether aluminium induced delayed type hypersensitivity manifests as a spectrum of severity rather than discrete entities warrants further investigation. Several outcomes including Alzheimer’s disease, bone disease, primary ovarian insufficiency, complex regional pain syndrome, and postural orthostatic tachycardia syndrome lacked eligible human studies, underscoring the need for further study. Animal, in vitro, and mechanistic studies were beyond the scope of this review, which focused on direct human evidence. Although preclinical data can inform understanding of biological mechanisms, findings from animal and laboratory studies cannot be directly applied to human health outcomes.

Conclusion

Current evidence does not support causal associations between aluminium adjuvanted vaccines and serious or long term health outcomes, including ASD, type 1 diabetes mellitus, asthma, and other chronic conditions. Local hypersensitivity reactions, such as persistent nodules and granulomas, represent the only consistently observed reactions and carry a favourable long term prognosis. These findings are consistent with the broader post-licensure safety evidence base, which supports continued use of aluminium adjuvanted vaccines in immunisation programmes. Ongoing investment in higher quality primary research remains important given the predominance of uncontrolled case series, the limited number of long term population based studies, and persistent evidence gaps for rare or delayed outcomes. Clear, evidence based communication remains essential to address concerns and support informed decision making.

What is already known on this topic

  • Post-licensure surveillance has broadly supported the safety of aluminium adjuvanted vaccines, although concerns about potential long term effects continue to arise in scientific and public settings

  • The cumulative human evidence addressing these questions has been fragmented and methodologically variable, and has not recently been comprehensively synthesised across outcomes

What this study adds

  • Current evidence does not support causal associations between aluminium adjuvanted vaccines and serious or long term health outcomes such as autism spectrum disorder, asthma, and autoimmune conditions

  • Persistent nodules or granulomas appear to be associated with aluminium adjuvanted vaccines and they are usually uncommon, local, and self-limited

  • These findings are consistent with the broader post-licensure safety evidence base, which supports continued use of aluminium adjuvanted vaccines in immunisation programmes

Acknowledgments

The authors thank Shannon Hayes (Health Library of Health Canada and Public Health Agency of Canada) for developing the search strategy and conducting the literature search; Christian Cao (University of Toronto) for conducting the automated initial screening of titles/abstract and full texts of the 2025 updated search with otto-SR; and Ana Howarth (Public Health Agency of Canada) for her contributions to knowledge translation and public communication considerations.

Web extra.

Extra material supplied by authors

Web appendix: Supplementary materials

doyp088921.ww.pdf (1.6MB, pdf)

Contributors: PD-P, EMA, RP, and JZ designed the study. PD-P, JC, and JZ assessed study eligibility. PD-P and JC conducted data extraction, critical appraisal and analysis. PD-P, JC, and JZ drafted the manuscript. EMA and RP provided clinical and methodological expertise. PD-P, JC, EMA, RP, KY, MT, and JZ reviewed and approved the final version. PD-P acts as the guarantor. AI assisted tool was used in one aspect of this systematic review. Otto-SR (version 2025), a large language model based screening tool, was used to facilitate title/abstract and full text screening of records identified in the 2025 updated search. All records flagged as potentially eligible by otto-SR were manually reviewed and verified by human reviewers. All final inclusions and exclusions were made by human reviewers. The corresponding author (JZ) attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Funding: This work was supported by the Public Health Agency of Canada, which provided institutional support in the form of staff time and resources as part of routine activities. The funder did not dictate the study design or the collection, analysis, interpretation of data, or approach to writing the article.

Competing interests: All authors have completed the ICMJE uniform disclosure form at https://www.icmje.org/disclosure-of-interest/ and declare: this work was conducted as part of routine activities of the Public Health Agency of Canada, which provided institutional support in the form of staff time and resources; no external funding was received for this work; no personal financial relationships with any organizations that may have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work. EMA additionally declares the following unpaid roles with potential relevance to the subject matter: president, Allergy Section, Canadian Paediatric Society; board member, Canadian Society of Allergy and Clinical Immunology; member, Joint Task Force on Allergy Parameters.

Transparency: The lead author (PD-P) affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects have been omitted; and that any deviations from the registered protocol (PROSPERO CRD42023462831) have been disclosed and explained.

Dissemination to participants and related patient and public communities: Because this systematic review did not involve recruitment of participants, there are no individual study participants to whom results can be directly disseminated. Findings will be disseminated through scientific publication, research networks relevant to vaccine safety and public health, and relevant professional and public health organisations.

Provenance and peer review: Not commissioned; externally peer reviewed.

Ethics statements

Ethical approval

Not required. This systematic review involved no primary data collection from human participants.

Data availability statement

All data underlying this systematic review were extracted from studies that are already publicly available. The data extraction form, risk of bias assessments, and GRADE certainty assessments are provided in the supplementary materials. Reconciled extracted data are available upon request.

References

  • 1. Baylor NW, Egan W, Richman P. Aluminum salts in vaccines—US perspective. Vaccine 2002;20(Suppl 3):S18-23. 10.1016/S0264-410X(02)00166-4  [DOI] [PubMed] [Google Scholar]
  • 2. HogenEsch H. Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine 2002;20(Suppl 3):S34-9. 10.1016/S0264-410X(02)00169-X  [DOI] [PubMed] [Google Scholar]
  • 3. Principi N, Esposito S. Aluminum in vaccines: does it create a safety problem? Vaccine 2018;36:5825-31. 10.1016/j.vaccine.2018.08.036  [DOI] [PubMed] [Google Scholar]
  • 4. Petrovsky N. Comparative safety of vaccine adjuvants: a summary of current evidence and future needs. Drug Saf 2015;38:1059-74. 10.1007/s40264-015-0350-4  [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Macrophagic myofasciitis and aluminum-containing vaccines. Wkly Epidemiol Rec 1999;74:337-48.10613107 [Google Scholar]
  • 6. Global Advisory Committee on Vaccine Safety . June 2012. Wkly Epidemiol Rec 2012;87:281-7. [PubMed] [Google Scholar]
  • 7. Jefferson T, Rudin M, Di Pietrantonj C. Adverse events after immunisation with aluminium-containing DTP vaccines: systematic review of the evidence. Lancet Infect Dis 2004;4:84-90. 10.1016/S1473-3099(04)00927-2  [DOI] [PubMed] [Google Scholar]
  • 8. Willhite CC, Karyakina NA, Yokel RA, Yenugadhati N, Wisniewski TM, Arnold IM, et al. Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts. Crit Rev Toxicol 2014;44:1-80 10.3109/10408444.2014.934439 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Nirenberg E, Maldonado YA, Hoffman SA. The role and safety of aluminum adjuvants in childhood vaccines. Pediatrics 2026;157:e2025074874. 10.1542/peds.2025-074874  [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Krauss SR, Barbateskovic M, Klingenberg SL, et al. Aluminium adjuvants versus placebo or no intervention in vaccine randomised clinical trials: a systematic review with meta-analysis and trial sequential analysis. BMJ Open 2022;12:e058795. 10.1136/bmjopen-2021-058795  [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. 10.1136/bmj.n71  [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Adverse events potentially associated with aluminum adjuvants included in vaccines: a systematic review. 2024. Available from: https://www.crd.york.ac.uk/PROSPERO/view/CRD42023462831.
  • 13. McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol 2016;75:40-6. 10.1016/j.jclinepi.2016.01.021  [DOI] [PubMed] [Google Scholar]
  • 14. Cao C, Arora R, Cento P, et al. Automation of systematic reviews with large language models. medRxiv. 2025:2025.06.13.25329541 10.1101/2025.06.13.25329541 . [DOI]
  • 15. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:l4898. 10.1136/bmj.l4898  [DOI] [PubMed] [Google Scholar]
  • 16. Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016;355:i4919. 10.1136/bmj.i4919  [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Munn Z, Barker TH, Moola S, et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth 2020;18:2127-33. [DOI] [PubMed] [Google Scholar]
  • 18.Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions: Cochrane; 2024. Available from: https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current.
  • 19.Neumann I, Schunemann H. The GRADE Book version 1.0 (updated September 2024): The GRADE Working Group; 2024. Available from: https://book.gradepro.org/.
  • 20. Erdohazi M, Newman RL. Aluminium hydroxide granuloma. Br Med J 1971;3:621-3. 10.1136/bmj.3.5775.621  [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Pembroke AC, Marten RH. Unusual cutaneous reactions following diphtheria and tetanus immunization. Clin Exp Dermatol 1979;4:345-8. 10.1111/j.1365-2230.1979.tb02649.x  [DOI] [PubMed] [Google Scholar]
  • 22. Slater DN, Underwood JC, Durrant TE, Gray T, Hopper IP. Aluminium hydroxide granulomas: light and electron microscopic studies and X-ray microanalysis. Br J Dermatol 1982;107:103-8. 10.1111/j.1365-2133.1982.tb00297.x  [DOI] [PubMed] [Google Scholar]
  • 23. Kaaber K, Nielsen AO, Veien NK. Vaccination granulomas and aluminium allergy: course and prognostic factors. Contact Dermatitis 1992;26:304-6. 10.1111/j.1600-0536.1992.tb00123.x  [DOI] [PubMed] [Google Scholar]
  • 24. Blennow M, Granström M, Strandell A. Adverse reactions after diphtheria-tetanus booster in 10-year-old schoolchildren in relation to the type of vaccine given for the primary vaccination. Vaccine 1994;12:427-30. 10.1016/0264-410X(94)90119-8  [DOI] [PubMed] [Google Scholar]
  • 25. Skowron F, Grézard P, Bérard F, Balme B, Perrot H. Persistent nodules at sites of hepatitis B vaccination due to aluminium sensitization. Contact Dermatitis 1998;39:135-6. 10.1111/j.1600-0536.1998.tb05865.x  [DOI] [PubMed] [Google Scholar]
  • 26. Authier FJ, Cherin P, Creange A, et al. Central nervous system disease in patients with macrophagic myofasciitis. Brain 2001;124:974-83. 10.1093/brain/124.5.974  [DOI] [PubMed] [Google Scholar]
  • 27. Bordet AL, Michenet P, Cohen C, et al. [Post-vaccination granuloma due to aluminium hydroxide]. Ann Pathol 2001;21:149-52. [PubMed] [Google Scholar]
  • 28. Gherardi RK, Coquet M, Cherin P, et al. Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. Brain 2001;124:1821-31. 10.1093/brain/124.9.1821  [DOI] [PubMed] [Google Scholar]
  • 29. Guis S, Mattei JP, Nicoli F, et al. Identical twins with macrophagic myofasciitis: genetic susceptibility and triggering by aluminic vaccine adjuvants? Arthritis Rheum 2002;47:543-5. 10.1002/art.10666  [DOI] [PubMed] [Google Scholar]
  • 30. Lacson AG, D’Cruz CA, Gilbert-Barness E, Sharer L, Jacinto S, Cuenca R. Aluminum phagocytosis in quadriceps muscle following vaccination in children: relationship to macrophagic myofasciitis. Pediatr Dev Pathol 2002;5:151-8. 10.1007/s10024001-0137-8  [DOI] [PubMed] [Google Scholar]
  • 31. Authier FJ, Sauvat S, Champey J, Drogou I, Coquet M, Gherardi RK. Chronic fatigue syndrome in patients with macrophagic myofasciitis. Arthritis Rheum 2003;48:569-70. 10.1002/art.10740  [DOI] [PubMed] [Google Scholar]
  • 32. Bergfors E, Björkelund C, Trollfors B. Nineteen cases of persistent pruritic nodules and contact allergy to aluminium after injection of commonly used aluminium-adsorbed vaccines. Eur J Pediatr 2005;164:691-7. 10.1007/s00431-005-1704-1  [DOI] [PubMed] [Google Scholar]
  • 33. Maubec E, Pinquier L, Viguier M, et al. Vaccination-induced cutaneous pseudolymphoma. J Am Acad Dermatol 2005;52:623-9. 10.1016/j.jaad.2004.12.021  [DOI] [PubMed] [Google Scholar]
  • 34. Rivas E, Gómez-Arnáiz M, Ricoy JR, et al. Macrophagic myofasciitis in childhood: a controversial entity. Pediatr Neurol 2005;33:350-6. 10.1016/j.pediatrneurol.2005.05.024  [DOI] [PubMed] [Google Scholar]
  • 35. Chong H, Brady K, Metze D, Calonje E. Persistent nodules at injection sites (aluminium granuloma)—clinicopathological study of 14 cases with a diverse range of histological reaction patterns. Histopathology 2006;48:182-8. 10.1111/j.1365-2559.2005.02312.x  [DOI] [PubMed] [Google Scholar]
  • 36. Clarke PD, Adams P, Ibáñez R, Herzog C. Rate, intensity, and duration of local reactions to a virosome-adjuvanted vs. an aluminium-adsorbed hepatitis A vaccine in UK travellers. Travel Med Infect Dis 2006;4:313-8. 10.1016/j.tmaid.2006.01.001  [DOI] [PubMed] [Google Scholar]
  • 37. Kalil RK, Monteiro A, Jr, Lima MI, et al. Macrophagic myofasciitis in childhood: the role of scanning electron microscopy/energy-dispersive spectroscopy for diagnosis. Ultrastruct Pathol 2007;31:45-50. 10.1080/01913120601169550  [DOI] [PubMed] [Google Scholar]
  • 38. Lach B, Cupler EJ. Macrophagic myofasciitis in children is a localized reaction to vaccination. J Child Neurol 2008;23:614-9. 10.1177/0883073807312370  [DOI] [PubMed] [Google Scholar]
  • 39. Surquin M, Tielemans CL, Kulcsár I, et al. Rapid, enhanced, and persistent protection of patients with renal insufficiency by AS02(V)-adjuvanted hepatitis B vaccine. Kidney Int 2010;77:247-55. 10.1038/ki.2009.454  [DOI] [PubMed] [Google Scholar]
  • 40. Tomljenovic L, Shaw CA. Do aluminum vaccine adjuvants contribute to the rising prevalence of autism? J Inorg Biochem 2011;105:1489-99. 10.1016/j.jinorgbio.2011.08.008  [DOI] [PubMed] [Google Scholar]
  • 41. Bergfors E, Trollfors B. Sixty-four children with persistent itching nodules and contact allergy to aluminium after vaccination with aluminium-adsorbed vaccines-prognosis and outcome after booster vaccination. Eur J Pediatr 2013;172:171-7. 10.1007/s00431-012-1841-2  [DOI] [PubMed] [Google Scholar]
  • 42. Gente Lidholm A, Bergfors E, Inerot A, Blomgren U, Gillstedt M, Trollfors B. Unexpected loss of contact allergy to aluminium induced by vaccine. Contact Dermatitis 2013;68:286-92. 10.1111/cod.12053  [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43. Ragunathan-Thangarajah N, Le Beller C, Boutouyrie P, et al. Distinctive clinical features in arthro-myalgic patients with and without aluminum hydroxyde-induced macrophagic myofasciitis: an exploratory study. J Inorg Biochem 2013;128:262-6. 10.1016/j.jinorgbio.2013.07.020  [DOI] [PubMed] [Google Scholar]
  • 44. Basavaraj VH, Sampath G, Hegde NR, Mohan VK, Ella KM. Evaluation of safety and immunogenicity of HNVAC, an MDCK-based H1N1 pandemic influenza vaccine, in phase I single centre and phase II/III multi-centre, double-blind, randomized, placebo-controlled, parallel assignment studies. Vaccine 2014;32:4592-7. 10.1016/j.vaccine.2014.05.039  [DOI] [PubMed] [Google Scholar]
  • 45. Konno R, Yoshikawa H, Okutani M, et al. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women. Hum Vaccin Immunother 2014;10:1781-94. 10.4161/hv.28712  [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46. Nevison CD. A comparison of temporal trends in United States autism prevalence to trends in suspected environmental factors. Environ Health 2014;13:73. 10.1186/1476-069X-13-73  [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47. Sobanjo-ter Meulen A, Vesikari T, Malacaman EA, et al. Safety, tolerability and immunogenicity of 15-valent pneumococcal conjugate vaccine in toddlers previously vaccinated with 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2015;34:186-94. 10.1097/INF.0000000000000516  [DOI] [PubMed] [Google Scholar]
  • 48. Santiago T, Rebelo O, Negrão L, Matos A. Macrophagic myofasciitis and vaccination: consequence or coincidence? Rheumatol Int 2015;35:189-92. 10.1007/s00296-014-3065-4  [DOI] [PubMed] [Google Scholar]
  • 49. Van Der Gucht A, Aoun Sebaiti M, Itti E, et al. Neuropsychological correlates of brain perfusion SPECT in patients with macrophagic myofasciitis. PLoS One 2015;10:e0128353. 10.1371/journal.pone.0128353  [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50. Leroux-Roels G, Marchant A, Levy J, et al. Impact of adjuvants on CD4(+) T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial. Clin Immunol 2016;169:16-27. 10.1016/j.clim.2016.05.007  [DOI] [PubMed] [Google Scholar]
  • 51. Poddighe D, Vadalà M, Laurino C, Palmieri B. Somatoform and neurocognitive syndromes after HPV immunization are not associated to cell-mediated hypersensitivity to aluminum. Toxicol In Vitro 2017;43:58-61. 10.1016/j.tiv.2017.06.003  [DOI] [PubMed] [Google Scholar]
  • 52. Burny W, Marchant A, Hervé C, et al. ECR-008 study group . Inflammatory parameters associated with systemic reactogenicity following vaccination with adjuvanted hepatitis B vaccines in humans. Vaccine 2019;37:2004-15. 10.1016/j.vaccine.2019.02.015  [DOI] [PubMed] [Google Scholar]
  • 53. Sechi A, Patrizi A, Vincenzi C, et al. Sonographic features of vaccination granulomas in children with delayed-type hypersensitivity to aluminum. Pediatr Dermatol 2019;36:1012-6. 10.1111/pde.13953  [DOI] [PubMed] [Google Scholar]
  • 54. Fournier C, Auger I, Houle MC. Wells syndrome (eosinophilic cellulitis) following vaccination: Two pediatric cases with positive patch test to aluminium salts. Contact Dermatitis 2020;82:401-2. 10.1111/cod.13485  [DOI] [PubMed] [Google Scholar]
  • 55. Hoffmann SS, Thyssen JP, Elberling J, Hansen KS, Johansen JD. Children with vaccination granulomas and aluminum contact allergy: Evaluation of predispositions, avoidance behavior, and quality of life. Contact Dermatitis 2020;83:99-107. 10.1111/cod.13538  [DOI] [PubMed] [Google Scholar]
  • 56. Kelly E, Leahy R, McDermott M, et al. Persistent pruritic subcutaneous nodules at injection sites and other delayed type hypersensitivity reactions to aluminium adsorbed vaccines in Irish children: a case series. Acta Paediatr 2020;109:2692-3. 10.1111/apa.15394  [DOI] [PubMed] [Google Scholar]
  • 57. Kim H, Lim KY, Kang J, Park JW, Park SH. Macrophagic myofasciitis and subcutaneous pseudolymphoma caused by aluminium adjuvants. Sci Rep 2020;10:11834. 10.1038/s41598-020-68849-8  [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58. Zanoni G, Migliorini M, Gallo T, Guidolin L, Schena D. Recurrent injection site reactions to vaccines: Two clinical patterns of presentation. Vaccine 2020;38:6985-9. 10.1016/j.vaccine.2020.08.073  [DOI] [PubMed] [Google Scholar]
  • 59. Glanz JM, Clarke CL, Daley MF, et al. The childhood vaccination schedule and the lack of association with type 1 diabetes. Pediatrics 2021;148:e2021051910. 10.1542/peds.2021-051910  [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60. Hoffmann SS, Thiesson EM, Johansen JD, Hviid A. Risk factors for granulomas in children following immunization with aluminium-adsorbed vaccines: a Danish population-based cohort study. Contact Dermatitis 2022;87:430-8. 10.1111/cod.14180  [DOI] [PubMed] [Google Scholar]
  • 61. Lidholm AG, Inerot A, Gillstedt M, Bergfors E, Trollfors B. Long-term clinical course and prognosis of vaccine-related persistent itching nodules (1997-2019): an observational study. Vaccine X 2022;11:100163. 10.1016/j.jvacx.2022.100163  [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62. Walsh EE, Falsey AR, Scott DA, et al. A randomized phase 1/2 study of a respiratory syncytial virus prefusion F vaccine. J Infect Dis 2022;225:1357-66. 10.1093/infdis/jiab612  [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.A phase 2B placebo-controlled randomized study of a respiratory syncytial virus (RSV) vaccine in pregnant women 2022 (updated 18 Oct 2022). Available from: https://clinicaltrials.gov/study/NCT04032093?term=NCT04032093&rank=1.
  • 64. Daley MF, Reifler LM, Glanz JM, et al. Association between aluminum exposure from vaccines before age 24 months and persistent asthma at age 24 to 59 months. Acad Pediatr 2023;23:37-46. 10.1016/j.acap.2022.08.006  [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65. Cox NH, Moss C, Forsyth A. Allergy to non-toxoid constituents of vaccines and implications for patch testing. Contact Dermatitis 1988;18:143-6. 10.1111/j.1600-0536.1988.tb04500.x  [DOI] [PubMed] [Google Scholar]
  • 66. Veien NK, Hattel T, Justesen O, Nørholm A. Aluminium allergy. Contact Dermatitis 1986;15:295-7. 10.1111/j.1600-0536.1986.tb01371.x  [DOI] [PubMed] [Google Scholar]
  • 67. Cominos D, Strutton G, Busmanis I. Granulomas associated with tetanus toxoid immunization. Am J Dermatopathol 1993;15:114-7. 10.1097/00000372-199304000-00003  [DOI] [PubMed] [Google Scholar]
  • 68. Cosnes A, Flechet ML, Revuz J. Inflammatory nodular reactions after hepatitis B vaccination due to aluminium sensitization. Contact Dermatitis 1990;23:65-7. 10.1111/j.1600-0536.1990.tb03224.x  [DOI] [PubMed] [Google Scholar]
  • 69. Fawcett HA, Smith NP. Injection-site granuloma due to aluminum. Arch Dermatol 1984;120:1318-22. 10.1001/archderm.1984.01650460058020  [DOI] [PubMed] [Google Scholar]
  • 70. Bovier PA, Farinelli T, Loutan L. Interchangeability and tolerability of a virosomal and an aluminum-adsorbed hepatitis A vaccine. Vaccine 2005;23:2424-9. 10.1016/j.vaccine.2004.11.024  [DOI] [PubMed] [Google Scholar]
  • 71. Chérin P, Menard D, Mouton P, et al. Macrophagic myofasciitis associated with inclusion body myositis: a report of three cases. Neuromuscul Disord 2001;11:452-7. 10.1016/S0960-8966(01)00194-8  [DOI] [PubMed] [Google Scholar]
  • 72. Miliauskas JR, Mukherjee T, Dixon B. Postimmunization (vaccination) injection-site reactions. A report of four cases and review of the literature. Am J Surg Pathol 1993;17:516-24. 10.1097/00000478-199305000-00012  [DOI] [PubMed] [Google Scholar]
  • 73. Bergfors E, Hermansson G, Nyström Kronander U, Falk L, Valter L, Trollfors B. How common are long-lasting, intensely itching vaccination granulomas and contact allergy to aluminium induced by currently used pediatric vaccines? A prospective cohort study. Eur J Pediatr 2014;173:1297-307. 10.1007/s00431-014-2318-2  [DOI] [PubMed] [Google Scholar]
  • 74. Salik E, Løvik I, Andersen KE, Bygum A. Persistent skin reactions and aluminium hypersensitivity induced by childhood vaccines. Acta Derm Venereol 2016;96:967-71. 10.2340/00015555-2432  [DOI] [PubMed] [Google Scholar]
  • 75. Andersson NW, Bech Svalgaard I, Hoffmann SS, Hviid A. Aluminum-adsorbed vaccines and chronic diseases in childhood : a nationwide cohort study. Ann Intern Med 2025;178:1369-77. 10.7326/ANNALS-25-00997  [DOI] [PubMed] [Google Scholar]
  • 76. Ackerson B, Sy LS, Slezak J, et al. Post-licensure safety study of new-onset immune-mediated diseases, herpes zoster, and anaphylaxis in adult recipients of HepB-CpG vaccine versus HepB-alum vaccine. Vaccine 2023;41:4392-401. 10.1016/j.vaccine.2023.06.004  [DOI] [PubMed] [Google Scholar]
  • 77. Marks KM, Kang M, Umbleja T, et al. ACTG 5379 (BEe-HIVe) Study Team . HepB-CpG vs HepB-Alum vaccine in people with HIV and prior vaccine nonresponse: the BEe-HIVe randomized clinical trial. JAMA 2025;333:295-306. 10.1001/jama.2024.24490  [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78. Bergfors E, Trollfors B, Inerot A. Unexpectedly high incidence of persistent itching nodules and delayed hypersensitivity to aluminium in children after the use of adsorbed vaccines from a single manufacturer. Vaccine 2003;22:64-9. 10.1016/S0264-410X(03)00531-0  [DOI] [PubMed] [Google Scholar]
  • 79. McClure DL, Hanson KE, Sundaram ME, et al. Incident epilepsy and vaccination status or vaccine aluminum exposure in children under age 4. J Pediatr 2026;292:115004. 10.1016/j.jpeds.2026.115004  [DOI] [PubMed] [Google Scholar]
  • 80. Taylor B, Miller E, Farrington CP, et al. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Lancet 1999;353:2026-9. 10.1016/S0140-6736(99)01239-8  [DOI] [PubMed] [Google Scholar]
  • 81. Madsen KM, Hviid A, Vestergaard M, et al. A population-based study of measles, mumps, and rubella vaccination and autism. N Engl J Med 2002;347:1477-82. 10.1056/NEJMoa021134  [DOI] [PubMed] [Google Scholar]
  • 82. Jain A, Marshall J, Buikema A, Bancroft T, Kelly JP, Newschaffer CJ. Autism occurrence by MMR vaccine status among US children with older siblings with and without autism. JAMA 2015;313:1534-40. 10.1001/jama.2015.3077  [DOI] [PubMed] [Google Scholar]
  • 83. Linneberg A, Jacobsen RK, Jespersen L, Abildstrøm SZ. Association of subcutaneous allergen-specific immunotherapy with incidence of autoimmune disease, ischemic heart disease, and mortality. J Allergy Clin Immunol 2012;129:413-9. 10.1016/j.jaci.2011.09.007  [DOI] [PubMed] [Google Scholar]
  • 84. Mitkus RJ, King DB, Hess MA, Forshee RA, Walderhaug MO. Updated aluminum pharmacokinetics following infant exposures through diet and vaccination. Vaccine 2011;29:9538-43. 10.1016/j.vaccine.2011.09.124  [DOI] [PubMed] [Google Scholar]
  • 85. Barbateskovic M, Klingenberg SL, Krauss SR, et al. Concentrations, number of doses, and formulations of aluminium adjuvants in vaccines: a systematic review with meta-analysis and trial sequential analysis of randomized clinical trials. Vaccines (Basel) 2023;11:1763. 10.3390/vaccines11121763  [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86. Moser CA, Offit PA. Aluminum exposure from vaccines and diet. JAMA 2026;335:939-42. 10.1001/jama.2026.0056  [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Web appendix: Supplementary materials

doyp088921.ww.pdf (1.6MB, pdf)

Data Availability Statement

All data underlying this systematic review were extracted from studies that are already publicly available. The data extraction form, risk of bias assessments, and GRADE certainty assessments are provided in the supplementary materials. Reconciled extracted data are available upon request.


Articles from The BMJ are provided here courtesy of BMJ Publishing Group

RESOURCES